On September 13, the Board of Directors of Cuu Long Pharmaceutical Joint Stock Company had a meeting with representatives of domestic and foreign investment groups and funds to visit the pharmaceutical factory of the company.

During this visit, DCL welcomed big companies, corporations and investment funds such as: Tong Yang Investment, Sarus Capital, Vietcombank Fund Management, SSIAM, Dream Incubator, Wardhaven, etc. The two sides had very open exchanges to look for potential opportunities for future cooperation.

Mr. Phi Xuan Truong, CLP’s Board of Directors’ representative, presented to the investors the overview of operation situation in all aspects from the product to the manufacturing facility; from the distribution network to the development strategy in the coming time of the business. “With more than 40 years in the field of pharmacy, Pharimexco – VPC has become a familiar, prestigious name with consumers, pharmacies and hospitals in the provinces of Vietnam.” said Mr. Truong “With the first-half revenue of 2017 alone, CLP achieved 51.12 billion VND of after tax profit, a sharp increase of 23.6% over the same period of 2016 (the same period was 41.36 billion VND). It is very clear that the company’s growth potential is shown.”

In the afternoon of the same day, representatives of corporations and investment funds also had time to visit CLP’s two drug manufacturing factories. This gives investors a more comprehensive and close-up view of the modern drug production process following CLP’s modern standards and strict quality control regulations.

Currently, Cuu Long Pharmaceutical has received great attention from investors as in early 2017, the company has acquired Euvipharm, one of the most modern pharmaceutical factories in Vietnam. In addition, CLP has a joint venture with SCIC and some investors to invest in a cancer drug factory, becoming the first cancer drug factory in Vietnam.

Moreover, in the first quarter of 2017, CLP started investing in the construction of the capsule 3 plant with a total investment of 363 billion VND to increase the production of hollow capsules by 270% which is a scarce supply in Vietnam. In addition, CLP is investing in more modern machinery and production lines to improve the quality of its products. Transforming the brand towards consumer friendliness along with improving the quality of Panalgan products (fever, flu, pain relief); etc. also confirmed the company’s efforts to building, strengthening and positioning firmly the brand in the domestic pharmaceutical market.

Simultaneously, CLP currently has three main warehouses located in key locations such as Hanoi, Ho Chi Minh City and Vinh Long to ensure timely delivery of products to the distribution network with more than 13 branches and more than 55 distributors spread from the North to South of the enterprise.

Because of its convergence factors for such extensive development, CLP is considered by investors to be one of the enterprises having competitive advantages over other peers.

“Vietnam’s economy is currently experiencing positive changes, especially the domestic pharmaceutical market has the strongest growth in Asia, the pharmaceutical companies with good prospects are receiving great attention from domestic and foreign investment funds. In the context of a wide open pharmaceuticals market, with strong investment and strategic orientation from its parent company, FIT Group, CLP has been creating a completely different competitive advantage compared to other pharmaceutical companies in Vietnam – This is the factor that we believe that no intelligent investor would like to miss when investing in the pharmaceutical market in Vietnam.” – Mr. Trinh Quoc Khanh, Deputy General Director in charge of Finance – Investment of CLP shared.